Ares Management (ARES) Q3 2025 10-Q Quarterly Report

Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR

Ares Management (ARES) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

Ares Management Q3 2025 10-Q Analysis

Management Discussion & Analysis

  • Revenue $2.40B, up 1% YoY (+$12M); nine months revenue $7.08B, up 2% YoY (+$141M) with 3% operational growth
  • Operating margin U.S. 83.2% vs 80.8% YoY Q3; International 68.6% vs 68.6% flat Q3; Nine months U.S. 83.7% vs 81.5%, Intl 69.8% vs 68.1%
  • Best performing: U.S. companion animal revenue +$1M Q3, +$172M nine months; Worst performing: U.S. livestock revenue down $25M Q3, $128M nine months due to MFA divestiture
  • Cash and equivalents $2.08B Sept 30, 2025 vs $1.99B Dec 31, 2024; Operating cash flow $2.01B for nine months (-$37M YoY); Capital expenditures increase led investing cash use $582M vs $441M
  • Near-term risks: US and global tariffs, disease outbreaks impacting livestock demand, foreign exchange headwinds, inflation; management maintains liquidity and debt covenant compliance; $4.5B share repurchase authorization remaining

Risk Factors

  • New risk: Impact of dynamic and unpredictable new tariffs and trade restrictions on costs and supply chains triggered by recent foreign trade policy changes
  • Most updated risk: Increased supply chain disruptions and labor/material cost volatility due to evolving tariffs and geopolitical tensions affecting third-party suppliers
  • Regulatory risk: Complex international sanctions compliance with example of prior OFAC investigation and July 2023 No Action letter concluding no further penalties
  • Operational risk: Potential supply shortages from sole-source third-party suppliers amid escalating trade disputes and import/export restrictions disrupting production
  • Financial risk: Exposure to rising manufacturing costs and inability to pass on full cost increases to customers could materially reduce operating results and financial condition

Ares Management Q3 2025 Quarterly Financials
XBRL

Revenue

$2.4B

+0.5% YoY -2.4% QoQ

Net Income

$721M

+5.7% YoY +0.4% QoQ

Net Margin

30.0%

+148bp YoY +85bp QoQ

Source: XBRL data from Ares Management Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Ares Management Quarterly Reports

Get deeper insights on Ares Management

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.